Alcon Inc. (ALC)
Alcon Q1 Earnings Miss Estimates, Stock Down, 2025 EPS View Lowered
ALC ends the first quarter of 2025 on a disappointing note.
Alcon (ALC) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Alcon (ALC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Ahead of Alcon (ALC) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Evaluate the expected performance of Alcon (ALC) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
ALC Stock May Rise With the Introduction of PanOptix Pro in US
Alcon introduces Clareon PanOptix Pro IOL to select practices across the United States, with commercial availability expected in May.
3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space
ALC, GKOS and REGN are well-positioned to benefit from the evolving space of cell-based ophthalmic therapy.
Alcon (ALC) Soars 6.0%: Is Further Upside Left in the Stock?
Alcon (ALC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Alcon Stock Might Rise as Clareon Vivity IOL Secures CE Mark Approval
ALC secures CE Mark for Clareon Vivity IOL, bringing advanced presbyopia-correcting lens technology to Europe, enhancing visual outcomes with cutting-edge innovation.
ALC Stock Rises Following the Merger Agreement With LENSAR
Alcon enters into a definitive merger agreement to acquire LENSAR's ALLY Robotic Cataract Laser Treatment System, proprietary Streamline software technology and LENSAR legacy laser system.
Is it the Right Time to Hold Alcon Stock in Your Portfolio Now?
ALC stays on investors' radar due to its Surgical arm performance and contributions from new products.
Alcon Stock Gains From Innovation Despite Macroeconomic Troubles
Within Vision Care, ALC is registering solid growth, banking on strong sales of its contact lenses and ocular health products.
Watch CNBC's full interview with Alcon CEO David Endicott
Alcon CEO David Endicott discusses the pharmaceutical firm's full-year results.
Alcon Inc. (ALC) Q4 2024 Earnings Call Transcript
Alcon Inc. (NYSE:ALC ) Q4 2024 Earnings Conference Call February 26, 2025 8:00 AM ET Company Participants Dan Cravens - Vice President, Investor Relations David Endicott - Chief Executive Officer Tim Stonesifer - Chief Financial Officer Conference Call Participants David Saxon - Needham & Company Jeff Johnson - Baird Ryan Zimmerman - BTIG Larry Biegelsen - Wells Fargo Julien Ouaddour - Bank of America Patrick Wood - Morgan Stanley David Adlington - JPMorgan Brett Fishbin - Keybanc Capital Markets Harry Shrives - Citi Tom Stephan - Stifel Issie Kirby - Redburn Atlantic Kavya Deshpande - UBS Jack Reynolds-Clark - RBC Capital Markets Chris Pasquale - Nephron Research LLC Anthony Petrone - Mizuho Group Michael Sarcone - Jefferies Operator Greetings, and welcome to the Alcon Fourth Quarter and 2024 Earnings Call. At this time, all participants are in a listen-only mode.
